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ABSTRACT
Background Percutaneous mitral valve repair (MVR)
using the MitraClip system has become a valid
alternative for patients with severe mitral regurgitation
(MR) and high operative risk.
Objective To identify clinical and periprocedural factors
that may have an impact on clinical outcome.
Design Multi-centre longitudinal cohort study.
Setting Tertiary referral centres.
Patients Here we report on the ﬁrst 100 consecutive
patients treated with percutaneous MVR in Switzerland
between March 2009 and April 2011. All of them had
moderate–severe (3+) or severe (4+) MR, and 62% had
functional MR. 82% of the patients were in New York
Heart Association (NYHA) class III/IV, mean left ventricular
ejection fraction was 48% and the median European
System for Cardiac Operative Risk Evaluation was 16.9%.
Interventions MitraClip implantation performed under
echocardiographic and ﬂuoroscopic guidance in general
anaesthesia.
Main outcome measures Clinical, echocardiographic
and procedural data were prospectively collected.
Results Acute procedural success (APS, deﬁned as
successful clip implantation with residual MR grade ≤2+)
was achieved in 85% of patients. Overall survival at 6
and 12 months was 89.9% (95% CI 81.8 to 94.6) and
84.6% (95% CI 74.7 to 91.0), respectively. Univariate
Cox regression analysis identiﬁed APS (p=0.0069) and
discharge MR grade (p=0.03) as signiﬁcant predictors of
survival.
Conclusions In our consecutive cohort of patients, APS
was achieved in 85%. APS and residual discharge MR
grade are important predictors of mid-term survival after
percutaneous MVR.
INTRODUCTION
Mitral regurgitation (MR) is the most common
cardiac valvular heart disease with a prevalence in a
general population of approximately 10% among
individuals above 75 year of age1 2 contributing sub-
stantially to morbidity and mortality,3–7 even inde-
pendently of left ventricular (LV) function.8 Surgical
mitral valve repair (MVR) is considered the treatment
of choice based on its superior long-term results com-
pared with mitral valve replacement or medical
therapy.9 10 However, many patients with
symptomatic severe MR and signiﬁcant comorbidities
or advanced age are denied surgery because of a high
surgical risk.11 Percutaneous MVR using the
MitraClip-system (Abbott Vascular, Abbott Park,
Illinois, USA) has recently emerged as a promising
novel transcatheter technique for the treatment of
severe MR. This technique is based on the surgical
edge-to-edge repair described by Alﬁeri12 where MR
is reduced by approximating the edges of both mitral
leaﬂets, thereby restoring valvular coaptation and cre-
ating a double-oriﬁce mitral valve. Its safety, feasibil-
ity, high procedural success rates and mid-term
durability have been established in several clinical
registries in the USA13 and Europe.14–18 A recent ran-
domised trial yielded superior safety of the MitraClip
procedure compared with surgical MVR; however,
after exclusion of transfusion, safety was similar in
both groups, whereas surgery provided better efﬁcacy
regarding sustained MR reduction.19 Of note, these
series as well as other recently published US
reports13 20 included predominantly patients with
degenerative MR, preserved LV function and low sur-
gical risk, and therefore potentially excluded a large
group of patients which may beneﬁt from the proced-
ure. However, a few small studies have shown feasi-
bility and high procedural success rates together with
improved short-term echocardiographic and clinical
outcomes in higher risk populations with predomin-
antly functional MR, reduced LV function and high
surgical risk.17 21
In spite of these encouraging studies, clinical
outcome following MitraClip treatment is not well
documented. It has been proposed that immediate
haemodynamic changes such as an increase in
cardiac index and a decrease in pulmonary artery
and wedge pressures may predict short-term out-
comes, and are associated with a low event rate at
follow-up.22 23 Nevertheless, data on other predic-
tors of mid-term clinical success or survival after
percutaneous MVR are currently lacking.
The aim of the present study was to identify clin-
ical and periprocedural factors predicting mid-term
clinical outcomes in the ﬁrst 100 patients undergoing
percutaneous MVR using the MitraClip system. This
registry represents the entire population treated by
percutaneous MVR in Switzerland prior to April
2011.
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METHODS
Study sample
Between February 2009 and April 2011, we consecutively
included the ﬁrst 100 patients undergoing percutaneous MVR
using the MitraClip system in a prospective national registry.
Four cardiac centres in Switzerland had introduced the proced-
ure, that is, Cardiocentro Ticino, the University Hospitals of
Zurich and Basel and Cantonal Hospital of Lucerne. All patients
had moderate-to-severe (3+) or severe (4+) MR of functional
or degenerative origin as graded according to current recom-
mendations of the American Society of Echocardiography.24
Patients were considered for the procedure if they met class I or
IIa indications for mitral valve surgery as recommended by the
European Society of Cardiology European Association for
Cardio-Thoracic Surgery guidelines on the management of
valvular heart disease 201210 and had a high surgical risk
(deﬁned by a logistic European System for Cardiac Operative
Risk Evaluation (EuroSCORE) mortality >15% or the presence
of speciﬁc surgical risk factors not covered by the EuroSCORE
(ie, frailty, immunosuppressive therapy, porcelain aorta or exten-
sive mediastinal radiation)). Furthermore, patients with func-
tional MR and a class IIb indication10 were eligible for
percutaneous MVR. Absolute exclusion criteria were rheumatic
heart disease and ﬂorid endocarditis, whereas the originally
applied ‘Everest criteria’20 (ie, a mitral valve oriﬁce area
<2.0 cm2, extensive prolapse of ﬂail leaﬂets (prolapse width
>25 mm, ﬂail gap >20 mm) or any interventional or surgical
procedure within 30 days following the index procedure) were
only considered as reference parameter but not as absolute
exclusion criteria. Indications for treatment of MR and individ-
ual surgical risk were assessed by an interdisciplinary HEART
team consisting of interventional cardiologists, echocardiogra-
phers, cardiac anaesthetists and cardiac surgeons. The local insti-
tutional review board approved the study protocol. All patients
gave written informed consent to be entered into the database.
Percutaneous MVR procedure
Percutaneous MitraClip implantation was performed under
general anaesthesia with echocardiographic (transesophageal)
and ﬂuoroscopic guidance, as extensively described previously.13–
16 19 20 22 In brief, after trans-septal puncture a 24-French
catheter-based delivery system is placed via the femoral vein in
the left atrium. Thereafter, the MitraClip is fed through the cath-
eter and directed towards the mitral valve where it is aligned with
the maximum jet originating from the regurgitant lesion.
Grasping and approximating the edges of the mitral leaﬂets in
the area of the maximal regurgitation jet results in a double
mitral oriﬁce and a signiﬁcant reduction of the MR. Acute pro-
cedural success (APS) was deﬁned as successful implantation of
one or more clips with a reduction of the MR to ≤2+.
Follow-up and outcome variables
Clinical and echocardiographic follow-up was scheduled at
6 months after the MVR procedure. Echocardiographic para-
meters were assessed in each individual centre. The severity of
MR was graded according to recommendations of the American
Society of Echocardiography.24 LV volumes and LV ejection frac-
tion (LVEF) were assessed using the biplane Simpson’s
method.25 LV end-diastolic and end-systolic diameters (LVEDD
and LVESD) as well as left atrial diameter were measured on
M-mode in the parasternal long axis view. Systolic pulmonary
pressures were estimated from measuring the pressure gradient
between right ventricle and right atrium in systole.
Clinical endpoints included all-cause mortality, NYHA func-
tional class26 and mitral valve surgery due to failure of percutan-
eous MVR. For regression analyses to yield potential predictors
of outcome, clinical and echocardiographic outcome variables
were grouped into a combined clinical efﬁcacy endpoint consist-
ing of survival, freedom from mitral valve surgery, absence of
postimplant congestive heart failure and persistent MR ≤2+ at
6 months follow-up. Bleeding was assessed according to the
Valve Academic Research Consortium (VARC) criteria.27
Statistical analysis
Descriptive statistics of the baseline characteristics are expressed
as number of observations (n), median and IQR or mean and
SD respectively for continuous variables whereas categorical
data are shown as percentages. To associate a nominal variable
to another nominal variable, we provided a frequency table as
well as a p value of either a χ2 or Fisher’s exact test, whichever
was appropriate. To compare a continuous variable between two
groups, we used Wilcoxon test or alternatively Student t test
presuming that the normality assumption has been met. As for
comparison of changes from baseline to follow-up, we provided
results of a t test applied to paired data. To associate a continu-
ous response variable to covariate while adjusting for the base-
line value of the response, we performed analysis of covariance.
Survival time is associated with a nominal variable using
log-rank test and to a continuous variable using Cox regression.
In addition, a Kaplan–Meier estimate is provided for all patients,
including a CI for the 75% quantile of time to survival, given
the fact that the median time of survival has not been reached.
Follow-up was assessed using inverted Kaplan–Meier esti-
mates.28 All CIs are computed at a conﬁdence level of 95%.
Given the large number of statistical tests (42 correlation tests to
survival and to the combined clinical efﬁcacy endpoint, respect-
ively) performed in this analysis the probability of a type I error
may be importantly inﬂated. For this reason we decided to
provide, whenever possible and reasonable, CIs rather than stat-
istical testing in this analysis. For all tests, we considered a p
value of <0.05 as statistically signiﬁcant. All analyses are done
using ‘R’ (R Development Core Team, 2010).
RESULTS
Patient sample and baseline characteristics
Between February 2009 and April 2011, 100 consecutive
patients treated in four centres were prospectively included in
the MitraSwiss registry (patient ﬂow is shown in ﬁgure 1). This
represents the entire population of patients treated by MitraClip
edge-to-edge MVR in Switzerland since its clinical introduction.
The median patient age was 77 years (IQR 18.5) and 23% were
female patients. All patients had MR grade 3+ or 4+. MR aeti-
ology was functional in 62% of patients and degenerative in
38%. Mean LVEF was 0.48 (SD 0.19) and the majority of the
patients were in functional class NYHA III or IV (82%) or had a
history of decompensated heart failure in the near past (77%).
The median surgical risk, as assessed by the logistic
EuroSCORE, was 17% (IQR 19). The remainder of the patient
baseline characteristics is given in table 1.
Results of the implantation procedure
The acute procedural results are summarised in table 2. In 54%
a single clip was sufﬁcient, whereas in 40% two clips and in 4%
of the patients three clips were implanted. APS was achieved in
85% of the cases (ﬁgure 2). In 52% of the patients MR grade
was reduced to 1+ and in 33% to 2+. We did not identify any
clinical or morphological factors predicting APS and there was
2 Sürder D, et al. Heart 2013;0:1–7. doi:10.1136/heartjnl-2012-303105
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no statistical difference in the APS rate when comparing func-
tional (APS=79%) or degenerative (APS=92%) MR. The dur-
ation of the intervention decreased along with growing
experience of the operators. For the ﬁrst 10 cases of each
centre, device time, deﬁned as the time from guide catheter
insertion to withdrawal of the delivery system into the guide
catheter, was 124 min (IQR 76; 95% CI 105 to 141). This par-
ameter signiﬁcantly decreased to 72.5 min (IQR 45.25; 95% CI
68 to 102) for the last 10 patients (p=0.004) indicating a rele-
vant learning curve for the technique (table 3). Similarly, an
increase in APS rate from 85% to 93% could be observed over
the same time period, although this change fell short of statis-
tical signiﬁcance.
Inhospital outcomes
Overall, serious life-threatening or fatal complications related to
the MitraClip procedure were rare. In all, 98% were extubated
immediately after or within 2 h after the procedure. Inhospital
death was 4% (table 2) and all cases occurred within the very
early individual experience of the technique: there was one peri-
procedural death due to rupture of a papillary muscle in an
84-year-old patient with severe MR and cardiogenic shock
10 days after acute myocardial infarction. This patient consented
to the MitraClip procedure as a salvage therapy in the face of
rapid medical deterioration without further therapeutic options.
A second patient died in hospital 2 months after unsuccessful
MitraClip procedure on the waiting list for heart transplant-
ation. In a third patient, an increase of the mean transvalvular
aortic gradient from 27 to 60 mm Hg occurred after successful
placement of one clip, with deterioration of LV function and
subsequent severe heart failure and death 2 days after the percu-
taneous MVR. In two patients (2%), the procedure was compli-
cated by a chordal rupture with acute worsening of the MR.
One of them immediately underwent surgical mitral valve
replacement but died 5 days postoperatively, whereas the second
patient was treated with intra-aortic balloon counterpulsation
and underwent successful mitral valve surgery 7 days later.
Follow-up outcomes
Clinical follow-up was complete within the surviving population
while echocardiographic follow-up was available in 78% of
patients. Missing echocardiographic data (n=22) included loss
to echocardiographic follow-up (n=10) and death (n=12 at
6 months).
The percentage of patients with MR grade ≤ 2+ at follow-up
was 78%, whereas 13% presented an MR grade 3+ and 9% an
MR grade 4+ (ﬁgure 2). Overall, 20% of the patients remained
in NYHA class III, and 80% of the patients were in class I or II
(ﬁgure 3). LV end-diastolic volume (LVEDV), indexed LVEDV,
LV end-systolic volume (LVESV), LV diameters (LVEDD and
LVESD) and systolic pulmonary artery pressure decreased sig-
niﬁcantly between baseline and follow-up (table 4). In an ana-
lysis of covariance, predictors for improvement of pulmonary
artery pressure at follow-up with respect to baseline were APS
(p=0.0017) and low MR grade at discharge (p global=0.0078;
Table 1 Baseline characteristics of the first 100 patients
Age—years (median; IQR) 77; 18.5
BMI (kg/m2) (median; IQR) 23.8; 5.3
Gender (male) (%) 67
Hypertension (%) 66
Hyperlipidaemia (%) 44
Diabetes (%) 13
Coronary artery disease (%) 45
Previous myocardial infarction (%) 34
Previous PCI (%) 31
Previous CABG (%) 17
Previous valve surgery (%) 6
Previous vascular surgery or of the thoracic aorta (%) 3
Previous episode of congestive heart failure (%) 77
NYHA class
I/II 18
III 62
IV 20
Comorbidities
COPD (%) 20
Previous cerebrovascular infarction (%) 9
Renal failure (%) 50
Cancer of any type (%) 11
Logistic EuroSCORE (%) (median; IQR) 16.9; 19.1
nt-proBNP (ng/l) (median; IQR) 3202; 3621
Chronic/intermittent atrial fibrillation (%) 52
Previous PM or ICD implantation (%) 28
CRT (%) 13
Mitral valve—grade of mitral regurgitation at baseline
Moderate to severe 30
Severe 70
MR aetiology
Functional/functional ischaemic 62
Degenerative 38
LVEF (mean; SD) 0.48; 0.19
LVEDV (ml) (mean; SD) 158; 92
LVESV (ml) (mean; SD) 93; 84
EDVI (ml/m2) (mean; SD) 87; 48
LA diameter (mm) (mean; SD) 51; 11
RV-RA gradient (mm Hg) (mean; SD) 47; 15
BMI, body mass index; BNP, brain natriuretic protein; CABG, coronary artery bypass
graft; COPD, chronic obstructive lung disease; CRT, cardiac resynchronisation therapy;
EDVI, end-diastolic volume index; EuroSCORE, European System for Cardiac Operative
Risk Evaluation; ICD, implantable cardioverter defibrillator; LA, left atrium; LVEDV, left
ventricular end-diastolic volume; LVEF, left ventricular ejection fraction; LVESV, left
ventricular end-systolic volume: PCI, percutaneous coronary intervention; PM,
pacemaker; RA, right atrium; RV, right ventricle.
Figure 1 Flowchart showing the fate of the 100 patients, treated
with MitraClip. APS, acute procedural success; MR, mitral regurgitation.
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p=0.0024 for MR >2+). No signiﬁcant change in LVEF and
left atrial diameter were seen during the follow-up.
LVEF, LV volumes and LV diameters have then been analysed
splitting the entire patient sample according to the mechanism
of MR (supplementary table S1). Not unexpected, the signiﬁ-
cant improvement in LV remodelling of the entire patient
sample seems to be mainly driven by the subgroup with
functional MR, where most of the decrease in LVEDV, LVESV,
LVEDD and LVESD appeared. On the other hand, the signiﬁ-
cant decrease in pulmonary artery pressure in the entire patient
sample was mainly driven by changes in the subgroup with
degenerative MR where a signiﬁcant decrease of nearly
10 mm Hg was observed (p=0.02).
Among adverse events which occurred during follow-up ﬁve
patients presented with single leaﬂet clip detachment, of which
four had degenerative MR. In three cases this was associated
with early clinical deterioration, and all three patients under-
went redo clipping (9–12 months after the initial intervention).
In two cases detachment was found at 3 and 6 months
follow-up, respectively, without any signs of clinical impairment.
Both these cases have been managed conservatively so far.
In one patient mitral valve replacement had to be performed
because of severe mitral stenosis detected 3 months after the
implantation of two clips. Reoperation rate at mid-term
was 5%.
Predictors of long-term efﬁcacy
The combined clinical efﬁcacy endpoint was met in 58 (64%) of
the patients at 6 months follow-up. Predictors for long-term efﬁ-
cacy were body mass index (inversely predictive) and MR grade
at discharge (table 5). The proportion of the efﬁcacy endpoint
was signiﬁcantly higher (p value Fisher‘s exact test: 0.0000002)
among patients with an MR grade of 1+ at discharge (89%)
compared with the patients with MR grade of 2+ (48%) or MR
grade of >2+ (15%). The mechanism of MR (p=0.63) and LV
volumes at baseline (p=0.78 for LVEDV and p=0.56 for
LVESV) did not directly inﬂuence on efﬁcacy.
The 75% quantile of overall survival was 23.4 months (95%
CI 12.10; Inf) with a median follow-up time of 15.77 months
(95% CI 14.20 to 18.07). A total of 20 deaths occurred. A low
MR grade at discharge (p=0.03) and APS (p=0.0069) were
identiﬁed as predictors of survival, highlighting the importance
of the initial procedural result (ﬁgure 4; supplementary
table S2). Interestingly, patients with MR grade 1+ at discharge
had a better prognosis than patients with an MR grade of 2+ or
more at discharge. Furthermore, congestive heart failure before
clip-implantation (p=0.04) and prior coronary artery bypass
grafting (CABG) (p=0.008) were identiﬁed as predictors of
mortality. Of note that 15 of 16 CABG patients had Functional
mitral regurgitation (FMR), and only in one patient,
Figure 2 Change of mitral
regurgitation grade from baseline to
discharge and to Follow-up.
Table 2 Periprocedural results and safety
No implanted clips (%)
Clip implantation not done/possible 2
1 clip 54
2 clips 40
3 clips 4
APS (%)
Overall 85
Functional MR 79*
Degenerative MR 92*
Inhospital mortality/morbidity (%)
Periprocedural mortality 1
Inhospital mortality 4
Cardiac surgery within 30 days 3
Periprocedural complications (%)
Artificial respiration >48 h 1
LVAD 1
Bleeding 6
Major bleeding 2
Complication due to transseptal puncture 3
Infection during hospital stay 1
Congestive heart failure during hospital stay 8
Cardiac arrhythmia during hospital stay 2
Chordal rupture 2
Papillary muscle rupture 1
Rupture of delivery catheter 1
Cerebrovascular infarction 1
Hospital stay—days
ICU/CCU stay—median (IQR) 1.6 (0)
Total hospital stay 6.5 (4)
*p Value for between group comparison 0.22.
APS, acute procedural success; CCU, coronary care unit; ICU, intensive care unit;
LVAD, left ventricular assist device; MR, mitral regurgitation.
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degenerative origin of the MR was predominant. The combin-
ation of functional MR and CABG is effectively a potent pre-
dictor of mortality (p=0.0042), whereas functional MR
without prior CABG (47 out of 62 patients) is not (ﬁgure 4;
supplementary table S2). Likewise, the presence of coronary
artery disease alone and baseline LV parameters (i.e. LV
volumes; LVEF) did not inﬂuence on patient’s survival.
DISCUSSION
The present report represents the Swiss experience with
MitraClip edge-to-edge percutaneous MVR. It consists of the
ﬁrst 100 patients treated by this technique and entered prospect-
ively into the MitraSwiss registry, a large nationwide collabora-
tive network database of centres in which this procedure is
performed. The results from this database indicate that the
MitraClip procedure is feasible and safe in a heterogeneous
population consisting of patients with predominantly functional
MR and reduced ejection fraction. APS (a reduction of MR to
2+ or less during the procedure), the severity of residual MR at
discharge and inhospital congestive heart failure emerged as pre-
dictors of mid-term outcome. This emphasises the importance
of obtaining an optimal result and a predischarge echocardiog-
raphy to predict the prognosis of the patient after MVR.
Percutaneous MVR, using the MitraClip system, is expanding
all over the world and particularly in Europe. Worldwide, the
system has already been used in more than 6000 patients. Even
in high-risk patients the technique has been shown to be safe
and feasible. However, evidence is limited to a few open-label
registries13–16 18 20 and one randomised study.19 Two series
focused on patients with severe LV dysfunction17 or patients
refractory to cardiac resynchronisation therapy and reported
similar results.21 In the European cohorts14–18 the majority of
the patients had functional MR, whereas in the endovascular
valve edge-to-edge repair study (EVEREST) II19 trial the major-
ity had degenerative mitral valve disease.
In contrast to the EVEREST13 19 20 series, 62% of the
patients in the present study had functional MR and many of
them had severe LV dysfunction and were therefore not consid-
ered suitable for surgery. The rate of successful MitraClip
implantation and the APS rate were over 80% and the acute
treatment effects were similar to the EVEREST13 19 20 series.
Long-term clinical results are characterised by an elevated rate
of all-cause mortality (16% at 12 months), which is not surpris-
ing for this high-risk patient population. In the surviving popu-
lation, the treatment effects are shown to be durable over time.
Nevertheless, there are still several questions regarding patient
selection and predictors of treatment success.
As previously reported by Franzen et al,17 our data indicate
that treatment of patients with severely depressed LVEF
using the MitraClip is feasible and safe. A potential explanation
for this is that the acute reduction in volume overload by redu-
cing the regurgitant volume could compensate for the immedi-
ate afterload increase, thus challenging the ‘pop-off ’ valve
concept.22 In fact no acute decompensation was seen in our
heart failure population even in those with a severely enlarged
LV and impaired LV function. Furthermore, our data do not
Table 4 Echocardiographic and biohumoral changes from baseline to follow-up.
Baseline (mean; SD) FU (mean; SD) Pairwise complete observations Mean difference p Value* 95% CI
LVEF 0.48; 0.19 0.48; 0.16 77 0 NS −0.63 to 0.6
LVEDV (ml) 158; 92 137; 63 52 16 0.00022 7.9 to 24.0
LVESV (ml) 93; 84 85; 67 52 9 0.02 1.5 to 16.5
EDVI (ml/m2) 87; 48 79; 39 52 9 0.00028 4.4 to 13.6
LVEDD (mm) 58.6; 12.1 55.8; 11.1 41 1.6 0.03 0.1 to 3.1
LVESD (mm) 43.2; 15.8 41.4; 14.0 36 2.1 0.06 −0.1 to 4.3
LA diameter (mm) 51; 11 49; 9 65 0 NS −1.63 to 1.6
RV-RA gradient (mm Hg) 47; 15 39; 15 62 7 0.0014 2.6 to 10.6
nt-proBNP (ng/l) 4474; 5885 2499; 3408 27 1126 0.03 98.5 to 2153.5
Data are given as mean±SD.
*p Value for between group comparisons of mean changes (only pairwise complete observations).
FU has been performed between 6 and 12 months after MitraClip implantation.
EDVI, end-diastolic volume index; LA, left atrium; LVEDD, left ventricular end-diastolic diameter; LVEDV, left ventricular end-diastolic volume; LVEF, left ventricular ejection fraction;
LVESD, left ventricular end-systolic diameter; LVESV, left ventricular end-systolic volume: RA, right atrium; RV, right ventricle.
Figure 3 Change of NYHA class from baseline to FU.
Table 3 Learning curve of the four implanting centres
Median; IQR 95% CI
Device time (min) Overall (n=100) 90; 68.5 92 to 112
First 10 patients/centre 124; 76* 105 to 141
Last 10 patients/centre 72.5; 45.25* 68 to 102
APS rate (%) Overall 85 –
First 10 patients/centre 85† –
Last 10 patients/centre 93† –
Wilcoxon t test for between group comparisons.
*p=0.004.
†Not significant.
APS, acute procedural success..
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indicate that APS or clinical efﬁcacy depend on whether the
aetiology of the MR was functional or degenerative.
The challenge for the future will be to perform further ana-
lyses in order to deﬁne well-validated clinical or echocardio-
graphic predictors of procedural success and to test the
intervention in a large randomised outcome trial. The so-called
echocardiographic `EVEREST criteria` may be of help to
predict feasibility and success of the intervention as well as to
reduce the rate of treatment failure. However, in European case
series many patients have been treated successfully despite not
meeting these criteria.
Failure of surgical MVR is generally deﬁned as recurrence of
moderate MR or worse. Therefore, a surgical intervention may
be considered successful only if the acute echocardiographic
result does not exceed residual trace or mild MR. Acute success
in percutaneous MVR has not been clearly deﬁned by an expert
committee. In the American series, Feldman and colleagues20
proposed the term APS for those MitraClip interventions with
technically successful delivery of one or more clips resulting in
an MR grade of 2+ or better, which correlates to less stringent
criteria when compared with surgical MVR. The acceptance of
partial MR reduction as treatment result after percutaneous
MVR may have been partially driven by the idea that complete
reduction of MR may be harmful, especially in patients with
functional MR and severe LV depression. Our data emphasise
the importance of an optimal echocardiographic result directly
after MitraClip implantation independent of LV function.
Patients with residual MR of grade 1+ or less had a better prog-
nosis than those with grade 2+ or more in terms of all-cause
Figure 4 Kaplan–Meier curves of
survival. (A) Survival depending on
mitral regurgitation (MR) grade after
MitraClip implantation (MR grade 1+:
black line; MR grade 2+: red line; MR
grade >2+: green line). (B) Survival of
patients with (red line) or without
acute procedural success (black line).
(C) Survival of patients with (red line)
or without (black line) episodes of
congestive heart failure in their clinical
history before MitraClip implantation.
(D) Survival of patients with functional
MR (FMR) without associated coronary
artery bypass grafting (CABG) in
medical history. (E) Survival of patients
with FMR and CABG in medical
history.
Table 5 Predictors for clinical efficacy
Age NS (−5.78, 4.43)*
BMI 0.01 (0.57, 4.27)*
Log EuroSCORE NS (−9.68, 4.67)*
Mechanism of MR NS†
Gender NS†
Previous myocardial infarction NS†
Previous CABG NS†
Congestive heart failure before MitraClip NS†
MR grade at discharge (1+ vs 2+ vs > 2+) 0.0000002†
Association between baseline variables and the combined clinical endpoint (freedom
from death at 6 months, freedom from MR grade ≥3+ at 6 months, freedom from
postimplant congestive heart failure and freedom from reoperation at 6 months).
*p Value, Wilcoxon t test (95% CI).
†χ2 Test.
BMI, body mass index; CABG, coronary artery bypass graft; EuroSCORE, European
System for Cardiac Operative Risk Evaluation; MR, mitral regurgitation.
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mortality and the combined clinical efﬁcacy endpoint at
6 months. Our data therefore clearly indicate that every effort
should be undertaken to avoid an insufﬁcient primary result of
the MitraClip procedure. APS remains to be an important
objective, but echocardiographic MR grade of 1+ may be the
optimal `treatment goal` for patients after percutaneous MVR
using the MitraClip system.
In conclusion, our data conﬁrm feasibility, safety and mid-term
efﬁcacy of percutaneous MVR using the MitraClip system, even
in a high-risk patient population with predominant functional
MR. Our data also clearly suggest that a patient’s prognosis may
depend directly on the initial procedural results (MR reduction
to <2+). Operators should therefore aim for an optimal acute
result, even in patients with a severely depressed LV function.
The limitations of the study are its observational nature
and open-label design and the absence of a control group.
Furthermore, multiple statistical testing may enhance the probabil-
ity of a type I error. Obviously the study has not been powered to
distinguish differences such as survival between subgroups. The
results of our study should therefore be considered as exploratory
and ‘hypothesis-generating’. Larger, ideally core-lab based studies,
are needed to conﬁrm them.
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